News | Heart Valve Technology | October 18, 2022

Foldax Appoints Gregory D. Casciaro as Chief Executive Officer

Gregory D. Casciaro

Gregory D. Casciaro 

 


October 18, 2022 —  Foldax, Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive Officer of the company, effective yesterday. In his more than 30 years in the medical technology arena, Casciaro has developed a track record of success leading and growing both private and public companies, from clinical through commercial phases, and from fundraising through acquisitions. He also brings strong strategic insights to the company as an experienced board member and advisor. 

As President and CEO of Access Closure, General Surgical Innovations, Orquest, and XTNT, he led all four companies to successful exits via acquisitions by, respectively, Cardinal Health, U.S. Surgical (now Medtronic), Johnson and Johnson (J&J), and Biosensors International. His experience also includes serving as President and CEO for Cardiac Dimensions, and in executive and management roles at Guidant’s Devices for Vascular Intervention division and North American Instrument Corp. Currently, he serves on the board of directors for Colospan, Cytokind, Tulavi Therapeutics and KL Acquisition Corp., and has held board roles with AngioDynamics, Apama Medical, Dextera Surgical, Kerberos Proximal Solutions, and QT Vascular. He has also served as strategic advisor for RenalPro

“Greg has enjoyed tremendous success leading and growing medtech companies, many of them in the cardiovascular space. His strategic guidance and leadership helped many of them navigate sometimes complex paths to market and resulted in successful acquisitions by industry leaders,” said Ken Charhut, Executive Chairman of the Board for Foldax. “We are delighted that Greg is joining us as we execute on our mission to bring a transformational heart valve platform to clinics and patients around the world.” 

“Foldax has a groundbreaking technology with the potential to solve perennial problems that have plagued heart valves for decades, and I am excited to lead the team working to make this promise a reality,” said Mr. Casciaro. “Reimagining how heart valves are designed and manufactured is a unique and special opportunity that I believe can benefit from my wealth of experiences.” 

For more information: www.foldax.com


Related Content

Feature | Cardiovascular Business | By Merilee Kern, MBA

Numerous indicators make clear that the next five years will usher in extreme transformation for a multitude of ...

Home November 09, 2022
Home
News | Cardiovascular Business

November 1, 2022 — Deepak L. Bhatt, MD, MPH, a top expert in cardiovascular medicine and interventional cardiology, has ...

Home November 01, 2022
Home
Feature | Cardiovascular Business

November 1, 2022 — Johnson & Johnson and Abiomed, a world leader in breakthrough heart, lung and kidney support ...

Home November 01, 2022
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the fields of diagnostic and interventional ...

Home November 01, 2022
Home
News | Cardiovascular Business

October 31, 2022 — The Yale School of Medicine announced the passing of Robert W. Berliner Professor Emeritus of ...

Home October 31, 2022
Home
News | Cardiovascular Business

October 24, 2022 — Asher Kimchi, MD, clinical chief of Cardiology, vice-clinical chief of the Department of Medicine ...

Home October 24, 2022
Home
News | Cardiovascular Business

October 20, 2022 — Atlas Healthcare Partners – which specializes in developing and managing ambulatory surgery centers ...

Home October 20, 2022
Home
News | Cardiovascular Business

October 19, 2022 — Mount Sinai Health System’s globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named ...

Home October 19, 2022
Home
News | Cardiovascular Business

October 12, 2022 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG ...

Home October 12, 2022
Home
News | Cardiovascular Business

October 6, 2022 – OpSens Inc., a Quebec-based medical device cardiology-focused company, has announced that it has ...

Home October 06, 2022
Home
Subscribe Now